Complete Conference Coverage Archive

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.

Metronomic Maintenance Therapy Significantly Improves Overall Survival in Rhabdomyosarcoma

Metronomic Maintenance Therapy Significantly Improves Overall Survival in Rhabdomyosarcoma

Researchers sought to determine if maintenance treatment with metronomic chemotherapy would improve survival outcomes in rhabdomyosarcoma.

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Acalabrutinib Monotherapy May Be Effective in the Treatment of Waldenstrom Macroglobulinemia

Acalabrutinib Monotherapy May Be Effective in the Treatment of Waldenstrom Macroglobulinemia

Previous studies have shown that acalabrutinib monotherapy may lead to improved outcomes among patients with treatment-naive or relapsed/refractory Waldenstrom macroglobulinemia.

Women With Head and Neck Cancer Receive Less Treatment and Have Inferior Outcomes Compared With Men

Women With Head and Neck Cancer Receive Less Treatment and Have Inferior Outcomes Compared With Men

When variables such as age and serious medical conditions were accounted for cancer versus non-cancer mortality was two times higher for women compared with men.

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.

Immune-Related Adverse Events During Anti-PD-1 Therapy May Increase Survival in Head and Neck Cancer

Immune-Related Adverse Events During Anti-PD-1 Therapy May Increase Survival in Head and Neck Cancer

It is believed that immune competence may modify anti-tumor response with anti-PD-1 therapy.

Quality-of-Life Outcomes for Pembrolizumab Compared With Standard of Care in Head and Neck Cancer

Quality-of-Life Outcomes for Pembrolizumab Compared With Standard of Care in Head and Neck Cancer

Two year treatment with pembrolizumab prolonged overall survival compared with standard of care among patients with HNSCC, but the effects on quality of life require further elucidation.

President's Address at ASCO 2018 Emphasizes Growth, Delivery, Reach of Precision Medicine

President's Address at ASCO 2018 Emphasizes Growth, Delivery, Reach of Precision Medicine

With precision medicine nearly 23% of all patients who present with advanced lung cancer are treated with FDA- or EMA-approved targeted therapies or immunotherapies instead of chemotherapy.

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.

Nivolumab Plus Cetuximab and Radiotherapy May Be a Safe Treatment Option in Head and Neck Cancer

Nivolumab Plus Cetuximab and Radiotherapy May Be a Safe Treatment Option in Head and Neck Cancer

Researchers sought to determine if the addition of nivolumab to radiotherapy and chemotherapy could improve outcomes among this patient population.

Nivolumab Plus Stereotactic Body Radiotherapy Fails To Improve Outcomes in Head and Neck Cancer

Nivolumab Plus Stereotactic Body Radiotherapy Fails To Improve Outcomes in Head and Neck Cancer

Although the addition of stereotactic body radiation therapy (SBRT) to nivolumab did not increase toxicity, it did not lead to any improvement in response rates or survival outcomes among patients with metastatic head and neck squamous cell carcinoma (HNSCC).

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

The increase in use of lenalidomide as maintenance treatment emphasizes the need to explore additional treatment options among patients with lenalidomide-refractory multiple myeloma.

Pomalidomide Plus Bortezomib, Dexamethasone Prolongs PFS in Relapsed/Refractory Multiple Myeloma

Pomalidomide Plus Bortezomib, Dexamethasone Prolongs PFS in Relapsed/Refractory Multiple Myeloma

Researchers randomly assigned 559 patients with relapsed/refractory multiple myeloma to receive bortezomib and dexamethasone with or without pomalidomide.

Symptom Assessment Intervention Led by Lay Health Workers Improved Patient Satisfaction and Reduced Health Care Use and Costs

Symptom Assessment Intervention Led by Lay Health Workers Improved Patient Satisfaction and Reduced Health Care Use and Costs

Lay health workers used phone calls to assess symptoms on a weekly basis for high-risk patients and on a monthly basis for low-risk patients.

Web-Based Monitoring Resulted in Longer Overall Survival for Patients in Lung Cancer

Web-Based Monitoring Resulted in Longer Overall Survival for Patients in Lung Cancer

Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.

Mobile Technology Is Useful in Collecting Patient-Reported Outcomes

Mobile Technology Is Useful in Collecting Patient-Reported Outcomes

The researchers also developed novel emoji PRO scales and associations between PROs and wearable data.

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.

Early, Attenuated-Dose Hypomethylating Agent Therapy May Be Effective in Low-Risk MDS

Early, Attenuated-Dose Hypomethylating Agent Therapy May Be Effective in Low-Risk MDS

The impact of this attenuated-dose hypomethylating agents among patients with low-risk myelodysplastic syndrome who are transfusion independent requires further investigation.

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.

Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL

Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL

The efficacy of nelarabine among newly diagnosed patients with T-cell ALL has not been fully explored.

Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations

Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations

Current literature reflects estimates, but not actual rates, of low-dose computed tomography adherence across the United States.

Cognitive Behavioral Therapy Compared With Acupuncture for Insomnia in Cancer Survivors

Cognitive Behavioral Therapy Compared With Acupuncture for Insomnia in Cancer Survivors

Investigators sought to determine whether cognitive behavioral therapy or acupuncture was more effective in addressing insomnia in this population.

CYCORE System May Improve Radiotherapy-Associated Symptoms in Head and Neck Cancer

CYCORE System May Improve Radiotherapy-Associated Symptoms in Head and Neck Cancer

The CYCORE system may enable physicians to intervene at the early signs of dehydration and other radiotherapy-associated symptoms.

Perioperative Gabapentin May Improve Pain Management in Head and Neck Cancer

Perioperative Gabapentin May Improve Pain Management in Head and Neck Cancer

The total morphine equivalents used were, however, not significantly different between arms.

ACA Decreased Non-Insurance Rates Among Patients With Head and Neck Cancer

ACA Decreased Non-Insurance Rates Among Patients With Head and Neck Cancer

These findings were, however, significant only in states that expanded Medicaid eligibility.

Acetaminophen May Decrease Opioid Use After Head and Neck Cancer Surgery

Acetaminophen May Decrease Opioid Use After Head and Neck Cancer Surgery

The number of PCA attempts did not differ between treatment arms.

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

Sentinel nodes were accurately identified in all 30 patients who underwent WLE.

Adjuvant Chemoradiotherapy Improves 5-Year OS in Salivary Squamous Cell Carcinoma

Adjuvant Chemoradiotherapy Improves 5-Year OS in Salivary Squamous Cell Carcinoma

Approximately 50% and 30% of patients with late- and early-stage disease, respectively, undergo surgery without adjuvant therapy.

Adjuvant Radiation May Improve Survival in Head and Neck Cancer

Adjuvant Radiation May Improve Survival in Head and Neck Cancer

The benefit of adjuvant radiotherapy in this setting was previously unestablished.

Celecoxib Reduces Opioid Use After Surgery in Head and Neck Cancer

Celecoxib Reduces Opioid Use After Surgery in Head and Neck Cancer

The mean total opioid morphine equivalent use in the celecoxib arm was 31.8 mg vs 45 mg in the control arm.

BLU-667 Promising in RET-Altered Solid Tumors

BLU-667 Promising in RET-Altered Solid Tumors

Doses of at least 60 mg yielded tumor reductions of 2% to 70% among 25 of the 30 evaluated patients.

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

At the time of final analysis, 192 of 302 patients had died.

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.

Rotavirus Vaccine May Overcome Immunotherapy Resistance

Rotavirus Vaccine May Overcome Immunotherapy Resistance

Researchers infected various tumor cell lines with anti-rotavirus vaccines confirmed to be PRR agonists.

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.

Tumor Cell Lysate Vaccine Shows Promise

Tumor Cell Lysate Vaccine Shows Promise

Antigen-specific T cells increased in frequency in vaccinated mice.

Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer

Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer

Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.

Uterine Re-Curettage May Not Affect Required Chemotherapy Courses in GTN

Uterine Re-Curettage May Not Affect Required Chemotherapy Courses in GTN

After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.

Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status

Bevacizumab Plus Chemotherapy Prolongs PFS in Endometrial Cancer With p53 Null Status

p53 mutational status may be a viable strategy upon which to base the course of therapy.

Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer

Adjuvant Chemotherapy Non-Inferior to Chemoradiotherapy in Cervical Cancer

There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.

One-Quarter of Patients With Gynecologic Cancer Cannot Afford Medical Care

One-Quarter of Patients With Gynecologic Cancer Cannot Afford Medical Care

Nearly half of patients were denied insurance coverage for a recommended treatment.

GTN: MTX With, Without Dactinomycin May Be Effective Option

GTN: MTX With, Without Dactinomycin May Be Effective Option

Patients in the single-course MTX+ACTD arm had a 46.81% CR rate after initial therapy.

Gynecologic Abdominal Surgery: Liposomal Bupivacaine May Reduce Opioid Use

Gynecologic Abdominal Surgery: Liposomal Bupivacaine May Reduce Opioid Use

Researchers randomly assigned 120 patients to receive bupivacaine HCl or liposomal bupivacaine.

Indocyanine Green Improves Sentinel Node Detection in Uterine Malignancies

Indocyanine Green Improves Sentinel Node Detection in Uterine Malignancies

Overall, 257 vs 527 SLNs were detected by isosulfan blue vs ICG, respectively.

Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery

Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery

There were no reported changes in pain scores after surgery.

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.

Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers

Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers

The impact of the ACA on health insurance access among women diagnosed with a gynecologic cancer was previously unestablished.

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

The impact of this treatment on quality of life was not previously reported.

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

The median follow-up was 17.6 months at time of interim analysis.

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.

PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer

PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer

Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve survival among patients with metastatic pancreatic adenocarcinoma.

Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer

Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer

The study arms had similar rates of adverse events, with 34.7% of patients in the cisplatin arm and 31.2% of patients in the S-1 arm reporting clinically relevant events.

RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer

RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer

Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy may be a lower-cost alternative, with better post-operative outcomes, to open transthoracic esophagectomy.

Extensive Intraoperative Peritoneal Lavage May Not Improve OS in Gastric Cancer

Extensive Intraoperative Peritoneal Lavage May Not Improve OS in Gastric Cancer

Previous research suggested that EIPL may improve survival by reducing the number of intraperitoneal-free cancer cells.

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.

Q&A With Martin Dreyling, MD, PhD, on Non-Hodgkin Lymphoma Research Presented at ASH

Q&A With Martin Dreyling, MD, PhD, on Non-Hodgkin Lymphoma Research Presented at ASH

Dr Dreyling, professor of medicine at the University of Munich Hospital, discusses research presented at the 2017 ASH Annual Meeting likely to have a clinical impact among patients with NHL.

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.

PET-CT Alone May Not Distinguish Richter Transformation in CLL

PET-CT Alone May Not Distinguish Richter Transformation in CLL

Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.

Axillary Node Management for Breast Cancer: Is Less More?

Axillary Node Management for Breast Cancer: Is Less More?

Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs